SEMA3F and osteosarcoma: Furthermore, higher expression of SEMA3F is correlated with better outcomes for various types of cancer patients, including osteosarcoma (26), esophageal cancer (27), breast cancer (30), head and neck squamous carcinoma (28), colorectal cancer (29, 31, 32), and prostate cancer (33).